Stereotaxis Inc increased forth quarter of 2024 net loss per share of $-0.09 compare to net loss per share of $-0.06 recorded in the same quarter a year ago a decrease compare to $-0.08 realized in previous quarter.
forth quarter of 2024
Earnings Per Share
Revenues
$ -0.09
$
7 Mill
$-0.03
$+3M+61.5 %
Stereotaxis Inc 's Revenue
rose by
61.5 % in forth quarter of 2024 (Dec 31 2024) year on year,
to $7 million and
declined by
-20.69 % sequentially.
Stereotaxis Inc in the forth quarter of 2024 recorded net loss of $-7.515 million, an increase from net loss of $-5.492 million in IV. Quarter a year ago.
Stereotaxis Inc Inventories Inventories declined by -1.13 % to $8.33 million from IV. Quarter a year ago, sequentially inventories fell by -7.53 %.
STXS's Cash flow
In the forth quarter of 2024 company's net cash flow was $1 million, capital expenditures grew by -0.366-99.45%, to $0 millions compare to same quarter a year ago
Stereotaxis Inc
does not pay out common stock dividend.
In trailing twelve-month period Stereotaxis Inc payed $ -0.10 cash per share, on a free-cash flow basis
.
Book value fell by -42.91 % sequentially to $0.07 per share, -18.29% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ -0.06 per share from $ -0.02.
Company
repurchased 1.31 million shares or 1.53 % in Dec 31 2024.
Stereotaxis Inc
does not pay out common stock dividend.
In trailing twelve-month period Stereotaxis Inc had negative $ -0.10 cash flow per share, on a free-cash flow basis
.
Book value fell by -42.91 % sequentially to $0.07 per share, -18.29% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ -0.06 per share from $ -0.02.
Company
repurchased 1.31 million shares or 1.53 % in Dec 31 2024.
Over the last five trading days, Stereotaxis Inc has experienced a decline in stock performance, with a decrease of -0.64%. As a result, the year-to-date performance of the company now stands at -26.19%. It is worth noting, however, that the stock is still trading 16.5% above its 52-week low. Looking at the financials for the April to June 30, 2023 time-frame, Stereotaxis Inc reported a loss of $-0.07 per share, which is the same as the previous year. Additionally, the company's revenue increased by 16.824% to $7.19 million compared to $6.15 million in the same quarter of the previous year. Sequentially, revenue also grew by 9.759% from $6.55 million. When compared to other companies in the Medical ...
Stereotaxis Inc has recorded a cumulative net loss of $-20 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -49.16%. The healthcare sector saw 409 other companies with a higher ROI, which is a cause for concern for investors. The ROI ranking has progressed in the Mar 31, 2023 quarter, moving up to 2788 from the total ROI ranking in the fourth quarter of 2022 at 4296. However, this does not change the fact that Stereotaxis Inc still falls behind many other healthcare companies in terms of ROI. For the fiscal span closing March 31, 2023, STXS increased i...
